248 related articles for article (PubMed ID: 35501832)
21. Effects of multi and selective targeted tyrosine kinase inhibitors on function and signaling of different bladder cancer cells.
Hänze J; Kessel F; Di Fazio P; Hofmann R; Hegele A
Biomed Pharmacother; 2018 Oct; 106():316-325. PubMed ID: 29966976
[TBL] [Abstract][Full Text] [Related]
22. RAS-MAPK Reactivation Facilitates Acquired Resistance in
Bockorny B; Rusan M; Chen W; Liao RG; Li Y; Piccioni F; Wang J; Tan L; Thorner AR; Li T; Zhang Y; Miao C; Ovesen T; Shapiro GI; Kwiatkowski DJ; Gray NS; Meyerson M; Hammerman PS; Bass AJ
Mol Cancer Ther; 2018 Jul; 17(7):1526-1539. PubMed ID: 29654068
[TBL] [Abstract][Full Text] [Related]
23. Rapidly acquired resistance to EGFR tyrosine kinase inhibitors in NSCLC cell lines through de-repression of FGFR2 and FGFR3 expression.
Ware KE; Marshall ME; Heasley LR; Marek L; Hinz TK; Hercule P; Helfrich BA; Doebele RC; Heasley LE
PLoS One; 2010 Nov; 5(11):e14117. PubMed ID: 21152424
[TBL] [Abstract][Full Text] [Related]
24. TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusion-Positive Intrahepatic Cholangiocarcinoma.
Goyal L; Shi L; Liu LY; Fece de la Cruz F; Lennerz JK; Raghavan S; Leschiner I; Elagina L; Siravegna G; Ng RWS; Vu P; Patra KC; Saha SK; Uppot RN; Arellano R; Reyes S; Sagara T; Otsuki S; Nadres B; Shahzade HA; Dey-Guha I; Fetter IJ; Baiev I; Van Seventer EE; Murphy JE; Ferrone CR; Tanabe KK; Deshpande V; Harding JJ; Yaeger R; Kelley RK; Bardelli A; Iafrate AJ; Hahn WC; Benes CH; Ting DT; Hirai H; Getz G; Juric D; Zhu AX; Corcoran RB; Bardeesy N
Cancer Discov; 2019 Aug; 9(8):1064-1079. PubMed ID: 31109923
[TBL] [Abstract][Full Text] [Related]
25. Identification of recurrent FGFR3-TACC3 fusion oncogenes from lung adenocarcinoma.
Capelletti M; Dodge ME; Ercan D; Hammerman PS; Park SI; Kim J; Sasaki H; Jablons DM; Lipson D; Young L; Stephens PJ; Miller VA; Lindeman NI; Munir KJ; Richards WG; Jänne PA
Clin Cancer Res; 2014 Dec; 20(24):6551-8. PubMed ID: 25294908
[TBL] [Abstract][Full Text] [Related]
26. FGFR1/3 tyrosine kinase fusions define a unique molecular subtype of non-small cell lung cancer.
Wang R; Wang L; Li Y; Hu H; Shen L; Shen X; Pan Y; Ye T; Zhang Y; Luo X; Zhang Y; Pan B; Li B; Li H; Zhang J; Pao W; Ji H; Sun Y; Chen H
Clin Cancer Res; 2014 Aug; 20(15):4107-14. PubMed ID: 24850843
[TBL] [Abstract][Full Text] [Related]
27. Complexity of FGFR signalling in metastatic urothelial cancer.
Rodriguez-Vida A; Saggese M; Hughes S; Rudman S; Chowdhury S; Smith NR; Lawrence P; Rooney C; Dougherty B; Landers D; Kilgour E; Arkenau HT
J Hematol Oncol; 2015 Oct; 8():119. PubMed ID: 26497743
[TBL] [Abstract][Full Text] [Related]
28. Mechanism of Oncogenic Signal Activation by the Novel Fusion Kinase FGFR3-BAIAP2L1.
Nakanishi Y; Akiyama N; Tsukaguchi T; Fujii T; Satoh Y; Ishii N; Aoki M
Mol Cancer Ther; 2015 Mar; 14(3):704-12. PubMed ID: 25589496
[TBL] [Abstract][Full Text] [Related]
29. Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo.
Lamont FR; Tomlinson DC; Cooper PA; Shnyder SD; Chester JD; Knowles MA
Br J Cancer; 2011 Jan; 104(1):75-82. PubMed ID: 21119661
[TBL] [Abstract][Full Text] [Related]
30. Targeted therapies: Expanding the role of FGFR3 inhibition in urothelial carcinoma.
Zengin ZB; Chehrazi-Raffle A; Salgia NJ; Muddasani R; Ali S; Meza L; Pal SK
Urol Oncol; 2022 Feb; 40(2):25-36. PubMed ID: 34840077
[TBL] [Abstract][Full Text] [Related]
31. Oncogenic Gene Fusion FGFR3-TACC3 Is Regulated by Tyrosine Phosphorylation.
Nelson KN; Meyer AN; Siari A; Campos AR; Motamedchaboki K; Donoghue DJ
Mol Cancer Res; 2016 May; 14(5):458-69. PubMed ID: 26869289
[TBL] [Abstract][Full Text] [Related]
32. Recurrent FGFR3-TACC3 fusion gene in nasopharyngeal carcinoma.
Yuan L; Liu ZH; Lin ZR; Xu LH; Zhong Q; Zeng MS
Cancer Biol Ther; 2014; 15(12):1613-21. PubMed ID: 25535896
[TBL] [Abstract][Full Text] [Related]
33. Fibroblast growth factor receptor (FGFR) inhibitors: A review of a novel therapeutic class.
Weaver A; Bossaer JB
J Oncol Pharm Pract; 2021 Apr; 27(3):702-710. PubMed ID: 33375902
[TBL] [Abstract][Full Text] [Related]
34. Analyses of FGFR3 and PIK3CA mutations in neuroblastomas and the effects of the corresponding inhibitors on neuroblastoma cell lines.
Kostopoulou ON; Holzhauser S; Lange BKA; Ohmayer A; Andonova T; Bersani C; Wickström M; Dalianis T
Int J Oncol; 2019 Dec; 55(6):1372-1384. PubMed ID: 31638167
[TBL] [Abstract][Full Text] [Related]
35. P4HA2-mediated HIF-1α stabilization promotes erdafitinib-resistance in FGFR3-alteration bladder cancer.
Li X; Li Y; Liu B; Chen L; Lyu F; Zhang P; He Q; Cheng L; Liu C; Song Y; Xing Y
FASEB J; 2023 Apr; 37(4):e22840. PubMed ID: 36943397
[TBL] [Abstract][Full Text] [Related]
36. Erdafitinib: A novel therapy for FGFR-mutated urothelial cancer.
Roubal K; Myint ZW; Kolesar JM
Am J Health Syst Pharm; 2020 Feb; 77(5):346-351. PubMed ID: 32073123
[TBL] [Abstract][Full Text] [Related]
37. Adipocyte Precursor-Derived NRG1 Promotes Resistance to FGFR Inhibition in Urothelial Carcinoma.
Hosni S; Kilian V; Klümper N; Gabbia D; Sieckmann K; Corvino D; Winkler A; Saponaro M; Wörsdörfer K; Schmidt D; Hahn O; Zanotto I; Bertlich M; Toma M; Bald T; Eckstein M; Hölzel M; Geyer M; Ritter M; Wachten D; De Martin S; Alajati A
Cancer Res; 2024 Mar; 84(5):725-740. PubMed ID: 38175774
[TBL] [Abstract][Full Text] [Related]
38. Co-active receptor tyrosine kinases mitigate the effect of FGFR inhibitors in FGFR1-amplified lung cancers with low FGFR1 protein expression.
Kotani H; Ebi H; Kitai H; Nanjo S; Kita K; Huynh TG; Ooi A; Faber AC; Mino-Kenudson M; Yano S
Oncogene; 2016 Jul; 35(27):3587-97. PubMed ID: 26549034
[TBL] [Abstract][Full Text] [Related]
39. Oncogenic driver FGFR3-TACC3 requires five coiled-coil heptads for activation and disulfide bond formation for stability.
Wang CG; Peiris MN; Meyer AN; Nelson KN; Donoghue DJ
Oncotarget; 2023 Feb; 14():133-145. PubMed ID: 36780330
[TBL] [Abstract][Full Text] [Related]
40. 1-tert-butyl-3-[6-(3,5-dimethoxy-phenyl)-2-(4-diethylamino-butylamino)-pyrido[2,3-d]pyrimidin-7-yl]-urea (PD173074), a selective tyrosine kinase inhibitor of fibroblast growth factor receptor-3 (FGFR3), inhibits cell proliferation of bladder cancer carrying the FGFR3 gene mutation along with up-regulation of p27/Kip1 and G1/G0 arrest.
Miyake M; Ishii M; Koyama N; Kawashima K; Kodama T; Anai S; Fujimoto K; Hirao Y; Sugano K
J Pharmacol Exp Ther; 2010 Mar; 332(3):795-802. PubMed ID: 19955487
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
